Precursor Preference in Surfactant Synthesis of Newborns - PowerPoint PPT Presentation

1 / 7
About This Presentation
Title:

Precursor Preference in Surfactant Synthesis of Newborns

Description:

... and Human Services. Precursor Preference in Surfactant Synthesis of Newborns ... Possible Recommendations the PAC Can Make to the Commissioner/Secretary ... – PowerPoint PPT presentation

Number of Views:96
Avg rating:3.0/5.0
Slides: 8
Provided by: gou1
Learn more at: http://www.fda.gov
Category:

less

Transcript and Presenter's Notes

Title: Precursor Preference in Surfactant Synthesis of Newborns


1
Precursor Preference in Surfactant Synthesis of
Newborns
  • Second Joint
  • Subpart D ReferralJune 29, 2005

2
Sara F Goldkind, MD, MAFDABioethicist Office
of the CommissionerOffice of Pediatric
Therapeutics
3
Possible Recommendations the PAC Can Make to the
Commissioner/Secretary
  • Recommend allowing the protocol to proceed
    because it satisfies 46.404/50.51, 46.405/50.52,
    or 46.406/50.53
  • Recommend allowing the protocol to proceed, with
    modifications, because it would satisfy
    46.404/50.51, 46.405/50.52, or 46.406/50.53
  • Recommend allowing the protocol to proceed, with
    or without modifications, because it would
    satisfy 46.407/50.54
  • Recommend that the protocol not be allowed to
    proceed, providing specific reasons

4
Findings to Support 46.407/50.54 Recommendation
  • The research presents a reasonable opportunity to
    further the understanding, prevention, or
    alleviation of a serious problem affecting the
    health or welfare of children
  • The research will be conducted in accordance with
    sound ethical principals, and
  • Adequate provisions are made for soliciting the
    assent of children and permission of their
    parents or guardians, as set for the in
    46.408/50.55

5
HHS and FDA Regulations regarding allowing a
protocol to proceed under
are comparable.
6
After Todays PAC Meeting
  • PAC recommendations will be transmitted by the
    Office of pediatric therapeutics, with comments,
    to FDA Commissioner (along with PES summary)
  • The FDA Commissioners determination will be
    transmitted by OHRP, with comments, to the
    Assistant Secretary for Health (along with PACs
    recommendation and PES summary)
  • The ASH will make the final determination on
    behalf of HHS Secretary

7
Possible Determinations of Secretary/Commissioner
  • Research in fact satisfies 46.404/50.51 or
    46.405/50.52 or 46.406/50.53
  • Support the research under 46.407/50.54 as
    submitted
  • Support the research under 46.407/50.54 with
    required and/or recommended modifications
  • Do not support the research
Write a Comment
User Comments (0)
About PowerShow.com